Actively Recruiting
Early Phase 1 Study of Personalized Tumor Vaccine mRNA-0217S001 with Pembrolizumab for Advanced Pancreatic Cancer
Led by Ruijin Hospital · Updated on 2023-10-26
54
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of the mRNA-0217S001 personalized tumor vaccine alone or combined with Pembrolizumab in patients with advanced pancreatic cancer. This early-phase study aims to observe immune responses, tumor control, progression-free survival, and overall survival in participants with locally advanced, recurrent, or metastatic solid tumors who have not responded to standard treatments. Participants receive the personalized neoantigen tumor vaccine during a dose escalation phase, and in a dose expansion phase, the vaccine is given together with Pembrolizumab. The vaccine targets tumor-specific antigens identified by gene sequencing and bioinformatics analysis. Treatment schedules and doses are adjusted according to the phase, with the primary focus on safety and immune response. During the study, participants undergo regular assessments including imaging to measure tumor response, blood tests to monitor immune cell activity and safety labs, and evaluations for adverse effects. The study monitors participants for up to 27 weeks for dose-limiting toxicity and immune responses and up to 105 weeks for tumor response and disease control. Long-term survival is followed for up to three years to assess overall outcomes and tolerability.
CONDITIONS
Brief Title
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
Research Team
X
Xinjing Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here